Kim Nguyen Chi
#133,021
Most Influential Person Now
Kim Nguyen Chi's AcademicInfluence.com Rankings
Kim Nguyen Chimedical Degrees
Medical
#2258
World Rank
#2667
Historical Rank
Oncology
#127
World Rank
#131
Historical Rank
Kim Nguyen Chiphilosophy Degrees
Philosophy
#6568
World Rank
#9624
Historical Rank
Logic
#3715
World Rank
#4913
Historical Rank
Download Badge
Medical Philosophy
Kim Nguyen Chi's Degrees
- Bachelors Biology University of California, Berkeley
- Doctorate Medicine Stanford University
Similar Degrees You Can Earn
Why Is Kim Nguyen Chi Influential?
(Suggest an Edit or Addition)Kim Nguyen Chi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (2004) (5412)
- Abiraterone and increased survival in metastatic prostate cancer. (2011) (3933)
- Increased survival with enzalutamide in prostate cancer after chemotherapy. (2012) (3907)
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009) (1682)
- Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer (2017) (1387)
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. (2012) (1189)
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
- Olaparib for Metastatic Castration-Resistant Prostate Cancer. (2020) (878)
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. (2019) (735)
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. (2019) (675)
- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. (2021) (478)
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. (2018) (401)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (398)
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer (2015) (379)
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. (2019) (364)
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. (2018) (326)
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. (2013) (290)
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. (2016) (284)
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (2020) (283)
- Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. (2016) (281)
- Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. (2012) (272)
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer (2017) (272)
- A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. (2005) (269)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
- Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. (2003) (256)
- Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. (2010) (252)
- Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. (2015) (251)
- Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. (2007) (250)
- Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. (2011) (229)
- Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. (2009) (224)
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer (2014) (224)
- Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer (2014) (209)
- A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. (2001) (201)
- Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. (2005) (197)
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. (2019) (194)
- Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. (2013) (185)
- Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors (2009) (183)
- Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease (2012) (182)
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. (2017) (174)
- Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. (2000) (162)
- A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer (2005) (161)
- Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. (2002) (158)
- Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. (2015) (152)
- Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients (2016) (147)
- Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer (2010) (143)
- A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel (2015) (138)
- Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry. (2001) (138)
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c (2011) (132)
- Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. (2010) (129)
- Morphological Differences between Circulating Tumor Cells from Prostate Cancer Patients and Cultured Prostate Cancer Cells (2014) (129)
- A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer (2008) (120)
- Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. (2010) (119)
- A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. (2008) (119)
- A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. (2002) (117)
- Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. (2005) (117)
- Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. (2008) (117)
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial (2017) (116)
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial (2017) (116)
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study (2021) (114)
- AR‐V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate (2017) (114)
- Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer (2013) (113)
- The standard of reporting of health-related quality of life in clinical cancer trials. (2000) (111)
- Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. (2019) (111)
- Continuous Flow Deformability-Based Separation of Circulating Tumor Cells Using Microfluidic Ratchets. (2016) (108)
- Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer (2017) (106)
- Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. (2014) (103)
- Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. (2018) (102)
- Intermittent chemotherapy in patients with metastatic androgen‐independent prostate cancer (2008) (100)
- DNA methylation landscapes in advanced prostate cancer (2020) (98)
- Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. (2015) (94)
- PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations (2019) (94)
- MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2. (2017) (93)
- The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). (2015) (88)
- Targeting heat shock proteins in metastatic castration-resistant prostate cancer (2015) (87)
- Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD) (2019) (86)
- Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. (2001) (85)
- Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial (2021) (85)
- Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel (2014) (83)
- A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. (2016) (80)
- C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer (2008) (80)
- Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events (2014) (79)
- Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. (2019) (78)
- Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. (2011) (76)
- High dose calcitriol may reduce thrombosis in cancer patients (2006) (76)
- Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. (2014) (75)
- A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer (2013) (74)
- Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. (2011) (73)
- Neoadjuvant Enzalutamide Prior to Prostatectomy (2016) (72)
- Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer (2015) (70)
- Size and deformability based separation of circulating tumor cells from castrate resistant prostate cancer patients using resettable cell traps. (2015) (69)
- Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. (2019) (69)
- Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events (2015) (69)
- Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. (2016) (68)
- A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer (2009) (66)
- Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model (2003) (66)
- Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. (2017) (65)
- Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. (2020) (64)
- Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2015) (63)
- Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression (2000) (63)
- Liquid biopsy: ready to guide therapy in advanced prostate cancer? (2016) (62)
- Timing Is Everything: Preclinical Evidence Supporting Simultaneous Rather Than Sequential Chemohormonal Therapy for Prostate Cancer (2005) (61)
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. (2013) (60)
- Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. (2019) (60)
- A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer (2019) (60)
- Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. (2013) (60)
- A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. (2017) (58)
- Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. (2017) (56)
- Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. (2017) (56)
- Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. (2019) (55)
- Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer (2021) (55)
- A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. (2005) (54)
- Targeting the apoptosis pathway in prostate cancer. (2013) (53)
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. (2019) (52)
- Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. (2019) (52)
- Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer (2005) (51)
- A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). (2004) (51)
- Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. (2019) (51)
- A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195 (2015) (50)
- C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial (2007) (50)
- A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer (2012) (50)
- A retrospective, Canadian multi‐center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration‐resistant prostate cancer (2014) (49)
- Erratum: Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039)) (2018) (48)
- Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations (2020) (47)
- Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer (2019) (47)
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer (2019) (47)
- Knock‐down of the Cytoprotective Gene, Clusterin, to Enhance Hormone and Chemosensitivity in Prostate and Other Cancers (2005) (46)
- Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC) (2005) (46)
- Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity (2019) (46)
- Integrated analysis of the prostate cancer small‐nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression (2015) (45)
- SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA (2017) (45)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (2018) (44)
- The DNA methylation landscape of advanced prostate cancer (2020) (44)
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer (2008) (44)
- SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. (2015) (43)
- Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. (2022) (42)
- Is prostate cancer screening cost‐effective? A microsimulation model of prostate‐specific antigen‐based screening for British Columbia, Canada (2014) (42)
- Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. (2012) (41)
- A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer (2012) (40)
- Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). (2021) (40)
- A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy (2008) (40)
- Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. (2022) (39)
- Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. (2015) (39)
- Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). (2012) (37)
- A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer (2005) (37)
- The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC. (2014) (36)
- Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. (2019) (36)
- Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATIT (2019) (36)
- BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression (2021) (36)
- Recognition and management of methemoglobinemia and hemolysis in a G6PD‐deficient patient on experimental anticancer drug Triapine (2006) (35)
- Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. (2011) (35)
- Targeting Anti-Apoptotic Genes Upregulated by Androgen Withdrawal Using Antisense Oligonucleotides to Enhance Androgen- and Chemo-Sensitivity in Prostate Cancer (2002) (35)
- Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. (2022) (35)
- First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter? (2005) (34)
- Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. (2009) (34)
- A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer (2018) (33)
- A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). (2017) (33)
- Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer. (2003) (33)
- Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. (2003) (32)
- Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group. (2003) (32)
- Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. (2020) (32)
- Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. (2006) (32)
- Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). (2015) (32)
- A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients (2014) (31)
- Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma (2018) (31)
- Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. (2020) (30)
- A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). (2012) (30)
- Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients (2018) (30)
- Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer (2019) (30)
- Prognostic Index Model for Progression‐Free Survival in Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone (2017) (29)
- LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC) (2020) (29)
- Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. (2018) (29)
- Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer (2012) (29)
- The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. (2017) (28)
- A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer (2014) (28)
- Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer (2012) (28)
- A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. (2012) (28)
- Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. (2019) (28)
- Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. (2016) (27)
- DNA repair defects in prostate cancer: impact for screening, prognostication and treatment (2018) (26)
- Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. (2010) (26)
- A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel (2008) (26)
- The impact of time to metastasis on overall survival in patients with prostate cancer (2018) (26)
- A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. (2012) (25)
- A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel. (2009) (25)
- Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. (2021) (25)
- Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial. (2021) (25)
- Antisense approaches in prostate cancer (2004) (24)
- Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. (2010) (24)
- A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. (2010) (24)
- Frequent mutation of the FOXA1 untranslated region in prostate cancer (2018) (24)
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. (2012) (23)
- Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study (2018) (23)
- Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. (2019) (23)
- Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. (2020) (23)
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer (2011) (22)
- Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer (2005) (22)
- Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition (2021) (22)
- Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy. (2018) (22)
- Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer (2007) (22)
- Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer (2012) (21)
- A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel. (2013) (21)
- NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies (2013) (21)
- Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer (2022) (21)
- Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. (2013) (21)
- Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis. (2015) (21)
- Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (21)
- Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America (2015) (20)
- Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic castration-resistant prostate cancer (mCRPC) screened in the PROfound study. (2021) (20)
- Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer (2008) (20)
- Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen (2013) (20)
- CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update. (2013) (19)
- A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. (2004) (18)
- Association of Baseline Corticosteroid with Outcomes in a Multivariate Analysis of the Phase 3 Affirm Study of Enzalutamide (ENZA), An Androgen Receptor Signaling Inhibitor (ARSI) (2012) (18)
- Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor. (2019) (18)
- A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies. (2014) (18)
- Interim results of a randomized phase 2 study of docetaxel with ramucirumab versus docetaxel in second-line advanced or metastatic urothelial carcinoma. (2015) (18)
- HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. (2020) (18)
- in Patients with Localized Prostate Cancer A Phase II Pharmacodynamic Study of Preoperative Figitumumab (2012) (17)
- A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. (2017) (17)
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. (2019) (17)
- Clinical effectiveness of docetaxel for castration‐sensitive prostate cancer in a real‐world population‐based analysis (2018) (17)
- Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. (2019) (17)
- Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial (2016) (17)
- A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154 (2005) (17)
- Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). (2012) (16)
- Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic. (2020) (16)
- Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. (2019) (16)
- OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. (2009) (16)
- Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors. (2015) (16)
- LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (2017) (16)
- Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature. (2013) (16)
- Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia. (2005) (16)
- Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. (2011) (15)
- A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone (2016) (15)
- Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN. (2020) (15)
- A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. (2015) (15)
- Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial. (2020) (15)
- Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. (2016) (15)
- Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study. (2020) (14)
- PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer. (2021) (14)
- A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209 (2018) (14)
- PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration. (2017) (13)
- Intermittent chemotherapy in metastatic androgen-independent prostate cancer (AIPC): Initial results from ASCENT. (2006) (13)
- Novel targeted therapies for prostate cancer. (2010) (13)
- Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane). (2020) (13)
- A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy (2004) (13)
- A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) (2007) (13)
- Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. (2008) (12)
- Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE) (2021) (12)
- Clinical utility of emerging liquid biomarkers in advanced prostate cancer. (2017) (12)
- The role of bisphosphonates in the management of bone metastases in prostate cancer. (2004) (12)
- Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. (2018) (12)
- Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. (2014) (11)
- Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2015) (11)
- Chemotherapy for metastatic castration‐sensitive prostate cancer (2016) (11)
- Impact of Enzalutamide, An Androgen Receptor Signaling Inhibitor, on Time to First Skeletal Related Event (SRE) and Pain in the Phase 3 Affirm Study (2012) (11)
- Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum. (2019) (11)
- A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. (2017) (11)
- Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. (2006) (11)
- Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). (2019) (11)
- 705 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE, IMPROVES SURVIVAL AND PRODUCES PSA AND RADIOGRAPHIC RESPONSES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACE (2011) (11)
- Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC). (2020) (11)
- Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy. (2014) (11)
- Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study (2020) (11)
- 610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations (2020) (10)
- Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2016) (10)
- Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. (2021) (10)
- A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer. (2012) (10)
- Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA). (2015) (10)
- Clinical Outcomes in Men of Diverse Ethnic Backgrounds with Metastatic Castration Resistant Prostate Cancer. (2020) (10)
- SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC). (2011) (10)
- Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2014) (10)
- 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). (2021) (10)
- Research in castration-resistant prostate cancer: what does the future hold? (2010) (10)
- Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors. (2006) (9)
- 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). (2019) (9)
- PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI). (2017) (9)
- A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. (2015) (9)
- TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) (2016) (9)
- Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP (2021) (9)
- Autoantibody Landscape in Patients with Advanced Prostate Cancer (2020) (9)
- Clinical Activity of Abiraterone Acetate (AA) after Progression on Mdv3100 in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC) (2012) (9)
- Impact of enzalutamide, an androgen receptor (AR) signalling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study (2012) (9)
- A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer (2021) (9)
- Differential treatment outcomes in BRCA1/2‐, CDK12‐, and ATM‐mutated metastatic castration‐resistant prostate cancer (2021) (9)
- Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial. (2019) (9)
- Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial. (2018) (9)
- Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN (2019) (9)
- Clinical implications of genomic alterations in metastatic prostate cancer (2021) (9)
- Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions (2010) (8)
- Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). (2009) (8)
- A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC–CTG) IND 130 (2005) (8)
- Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study. (2018) (8)
- Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer (2019) (8)
- A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. (2004) (8)
- 1142: Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy Prior to Radical Prostatectomy for Patients with High Risk Localized Prostate Cancer: Pathologic Outcomes and 3-Year Follow-Up Analyses (2007) (8)
- Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group (2008) (8)
- NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). (2013) (8)
- 757OGALETERONE IN 4 PATIENT POPULATIONS OF MEN WITH CRPC: RESULTS FROM ARMOR2. (2014) (8)
- Efficacy and tolerability of first-line abiraterone + prednisone (ABI) versus enzalutamide (ENZ) for metastatic castration-resistant prostate cancer (mCRPC) in men ≥ 80 years: A retrospective cohort study. (2018) (8)
- Reduced thromboembolic events with DN-101 (high-dose calcitriol) treatment of androgen-independent prostate cancer: Hypothesis for a new class of anticoagulants. (2006) (8)
- AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). (2021) (8)
- CCTG IND 232: A phase II study of durvalumab with or without tremelimumab in patients with metastatic castration resistant prostate cancer (mCRPC) (2019) (8)
- Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. (2018) (8)
- 783OBenefits of Abiraterone Acetate Plus Prednisone (AA+P) When Added to Androgen Deprivation Therapy (ADT) in LATITUDE on Patient (Pt) Reported Outcomes (PRO) (2017) (7)
- A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa). (2010) (7)
- Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a). (2004) (7)
- Overall survival between African-American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC). (2018) (7)
- The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors (2022) (7)
- Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC). (2017) (7)
- 755OA RANDOMIZED PHASE 3 STUDY COMPARING FIRST-LINE DOCETAXEL/PREDNISONE (DP) TO DP PLUS CUSTIRSEN IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). (2014) (7)
- Results of a randomized phase II study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment (2007) (7)
- Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC). (2020) (7)
- 7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC) (2009) (6)
- Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993). (2018) (6)
- Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy. (2017) (6)
- Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). (2021) (6)
- Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. (2021) (6)
- A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer. (2014) (6)
- Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). (2005) (6)
- Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial (2019) (6)
- Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. (2017) (6)
- Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. (2014) (6)
- A Canadian consensus forum on the management of patients with advanced prostate cancer. (2019) (6)
- The Pacific trial: A randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA). (2013) (6)
- Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study (2020) (6)
- Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. (2018) (6)
- Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. (2021) (6)
- Genomic analysis of circulating tumor DNA (ctDNA) in plasma of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (abi) and enzalutamide (enza). (2014) (6)
- Management algorithms for metastatic prostate cancer. (2019) (6)
- Safety and efficacy of apalutamide in Japanese patients with metastatic castration‐sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo‐controlled, phase III TITAN study (2022) (5)
- A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC). (2018) (5)
- Immunogenomic landscape of neuroendocrine small cell prostate cancer. (2019) (5)
- First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). (2019) (5)
- The future of systemic therapies for localised prostate cancer. (2013) (5)
- 4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2 (2014) (5)
- A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (2008) (5)
- Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone. (2017) (5)
- A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer. (2019) (5)
- A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641) (2019) (5)
- Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer. (2018) (5)
- Preventing patupilone-induced diarrhea with high-dose corticosteroids. (2010) (5)
- 1098 ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE HAS A FAVORABLE SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PROGRESSING AFTER DOCETAXEL-BASED CHEMOTHERAPY: RESULTS FROM COU-AA-301, A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE III STUDY (2011) (5)
- LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO). (2018) (5)
- A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone (2007) (5)
- Toward predictive signatures of enzalutamide response and resistance. (2015) (5)
- Abstract C41: A phase 1 study of OMN54 in patients with advanced malignancies (2015) (5)
- Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302 (2022) (5)
- Plasma miR371 for the detection of viable germ cell tumor in testicular cancer patients with enlarging or post chemotherapy residual nodes. (2018) (4)
- Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). (2022) (4)
- Apalutamide for patients with metastatic castration-sensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial (2021) (4)
- PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. (2022) (4)
- genitourinary tumours, prostateFinal overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC) (2016) (4)
- Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (2014) (4)
- Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer. (2018) (4)
- The neoadjuvant management of bladder cancer in Canada: A survey of genitourinary medical oncologists. (2011) (4)
- IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. (2015) (4)
- What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
- Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy (2016) (4)
- Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study. (2010) (4)
- The 5-Hydroxymethylcytosine Landscape of Prostate Cancer (2022) (4)
- Correlation of a novel whole blood RT-PCR assay measuring AR-V7 expression with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI). (2016) (4)
- Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase I trial: A new approach for enhancing the activity of combination chemotherapy (2007) (4)
- A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D). (2011) (4)
- Updated results from a randomized phase II study of cabazitaxel (CAB) versus abiraterone (ABI) or enzalutamide (ENZ) in poor prognosis metastatic CRPC. (2019) (4)
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC). (2006) (4)
- Molecular dissection of primary mediastinal germ cell tumors. (2017) (4)
- PD10-11 APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES (2020) (4)
- 7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC) (2009) (4)
- 576MO Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (2021) (4)
- Association of detectable levels of circulating tumor DNA (ctDNA) with disease burden in prostate cancer (PC). (2020) (4)
- Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy. (2012) (4)
- Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts). (2006) (4)
- Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). (2014) (4)
- Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA). (2014) (4)
- 834TiPRandomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC) (2017) (3)
- 788PEFFICACY OF ENZALUTAMIDE (ENZA) FOLLOWING ABIRATERONE ACETATE (ABI) IN CHEMOTHERAPY-NAïVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS). (2014) (3)
- LBA4_PRRANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (2017) (3)
- The neoadjuvant management of muscle-invasive bladder cancer (MIBC) in Canada: A national survey of urologists. (2012) (3)
- Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. (2021) (3)
- Genomic analysis of circulating cell-free DNA (cfDNA) to investigate mechanisms of resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (2015) (3)
- Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies. (2019) (3)
- 794PEPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy (2017) (3)
- Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. (2018) (3)
- 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). (2019) (3)
- Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2015) (3)
- Benefit Of Abiraterone Acetate Plus Prednisone (AA+P) Added To Androgen Deprivation Therapy (ADT) In Patients With High-Risk, Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): Post Hoc Analysis Of EQ-5D-5L From The Latitude Study (2018) (3)
- Genitourinary tumors, prostate (2012) (3)
- Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis. (2019) (3)
- 916PBiological assessment of viable germ cell tumor (VT) in patients (pts) with seminoma (S) and non-seminoma (S) using miR371 (2017) (3)
- Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. (2020) (3)
- Circulating tumor DNA (ctDNA) burden and actionable mutations in treatment-naïve metastatic castration-resistant prostate cancer (mCRPC). (2016) (3)
- 2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma (2015) (3)
- 299 POSTER Randomized phase II trial of irofulven/prednisone, irofulven/capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients failing first-line docetaxel: preliminary results (2006) (3)
- Androgen deprivation for prostate cancer: when and how, the good and the bad. (2013) (3)
- Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts). (2015) (3)
- PD28-04 DETECTION OF ANDROGEN RECEPTOR VARIANT 7 (AR-V7) IN WHOLE BLOOD RNA OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS TREATED WITH ABIRATERONE ACETATE (ABI) (2016) (3)
- A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC) (2012) (3)
- 706 POSTER A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies (2007) (3)
- Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2016) (3)
- Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC) (2016) (3)
- A Phase I Dose Finding Study of Cisplatin, Gemcitabine, and Weekly Docetaxel for Patients With Advanced Transitional Cell Cancer (2006) (2)
- Carboplatin and Vinblastine for the Treatment of Metastatic Transitional Cell Carcinoma of the Urothelial Tract (2002) (2)
- The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial (2021) (2)
- Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC). (2022) (2)
- Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. (2014) (2)
- Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer. (2023) (2)
- Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease. (2020) (2)
- Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate (2020) (2)
- Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC). (2013) (2)
- Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial. (2018) (2)
- RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results. (2018) (2)
- A phase II study of sorafenib in combination with bicalutamide in patients with chemo-naive hormone refractory prostate cancer (HRPC) (2008) (2)
- MP87-18 ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) (2015) (2)
- Abstract PO-077: Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH) - Trial in progress (2021) (2)
- Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). (2006) (2)
- Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. (2020) (2)
- Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up. (2012) (2)
- Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA. (2017) (2)
- Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study. (2022) (2)
- Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer. (2018) (2)
- Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44]. (2017) (2)
- 2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC) (2015) (2)
- Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as first-line treatment for patients with stage IIB/IV non-small cell lung cancer (NSCLC). (2006) (2)
- 693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy (2021) (2)
- Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. (2021) (2)
- Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM. (2018) (2)
- Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses (2007) (2)
- Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC). (2017) (2)
- 5-hydroxymethylcytosine as a liquid biopsy biomarker in mCRPC. (2021) (2)
- 618P Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN (2021) (2)
- The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN. (2022) (2)
- Gatekeeping in cancer clinical trials in Canada: The ethics of recruiting the “ideal” patient (2020) (2)
- Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). (2012) (2)
- Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer. (2018) (2)
- A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. (2012) (2)
- 648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC (2021) (2)
- PD34-11 PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES (2021) (2)
- Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2020) (2)
- A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab in Patients with Localized Prostate Cancer (2012) (2)
- Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (2)
- Apalutamide for the treatment of metastatic castration-sensitive prostate cancer. (2020) (2)
- Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH). (2021) (2)
- Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer. (2019) (2)
- Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound (2022) (2)
- An open label safety and efficacy phase 2a study of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing solid tumors (2016) (2)
- Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2021) (2)
- Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) patients (2022) (2)
- Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. (2006) (2)
- Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis (2020) (2)
- TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors (2022) (2)
- Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study (2022) (2)
- Real-world experience with docetaxel for castration-sensitive prostate cancer from a population-based analysis. (2018) (1)
- Abstract A18: Plasma circulating tumor DNA is scarce and confounded by clonal hematopoiesis in metastatic renal cell carcinoma (2020) (1)
- Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration‐naive prostate cancer: Results from LATITUDE (2018) (1)
- 246: Palliative Radiotherapy for Bone Metastases in Patients Dying of Prostate Cancer: The British Columbia Experience (2016) (1)
- New research in prostate cancer, ASCO-GU 2017. (2017) (1)
- Reply to the letter "About sorafenib in castration-resistant prostate cancer" by G. Colloca, F. Checcaglini and A. Venturino. (2008) (1)
- Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) (2019) (1)
- Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma. (2019) (1)
- A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE). (2020) (1)
- Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor. (2019) (1)
- HSD3B1 (1245A>C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (AA) and enzalutamide (ENZA): Results from two prospective studies. (2020) (1)
- A phase I study of ABT-751 in combination with docetaxel in patients with metastatic hormone-refractory prostate cancer. (2006) (1)
- Surrogates for Clinical Development (2008) (1)
- A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641). (2020) (1)
- Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel (2020) (1)
- Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study. (2022) (1)
- CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY (2009) (1)
- Exposure-adjusted safety analyses of the VISION phase 3 trial of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. (2022) (1)
- Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade (2022) (1)
- 2535 Clinical outcomes in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis (2015) (1)
- Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma. (2019) (1)
- 582P Health-related quality of life (HRQoL) at final analysis of the GALAHAD study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA repair defects (DRD) (2021) (1)
- Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): Long-term follow-up. (2012) (1)
- Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC). (2013) (1)
- A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993). (2015) (1)
- Developing prognostic models for advanced prostate cancer when the goal line keeps changing. (2018) (1)
- Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA). (2018) (1)
- Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP) (2006) (1)
- Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient Outcomes. (2020) (1)
- Hormonal therapy for prostate cancer: can bicalutamide-induced gynecomastia and breast pain be prevented? (2006) (1)
- Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo (2017) (1)
- Dehydroepiandrosterone (DHEA) in metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Dream Team (WCDT). (2016) (1)
- 564 Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (2015) (1)
- Frequent mutation of the FOXA1 untranslated region in prostate cancer (2018) (1)
- Patterns of prostate cancer management across Canadian prostate cancer treatment specialists. (2018) (1)
- A Phase I/II Study of Combination Neoadjuvant Hormone Therapy and Weekly OGX-011 Prior to Radical Prostatectomy in Patients with Localized Prostate Cancer (2006) (1)
- 512 NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion (2010) (1)
- A phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancer. (2012) (1)
- A Phase II Study of SB939 in Patients (PTS) with Castration Resistant Prostate Cancer (CRPC) (2012) (1)
- 7058 POSTER Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) – a Drug-Drug Interaction (DDI) Study With Dextromethorphan HBr and Theophylline (2011) (1)
- MP78-01 THE BURDEN OF SKELETAL-RELATED EVENTS ON PAIN OUTCOMES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (2014) (1)
- Plasma exosome microRNA-155 expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: A potential biomarker of response to systemic therapy. (2021) (1)
- Two decades in review: Progress in the treatment of mCRPC (2014) (1)
- A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209. (2017) (1)
- Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
- Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer. (2023) (1)
- Medical resource utilization (MRU) of abiraterone acetate plus prednisone (AAP) added to androgen deprivation therapy (ADT) in metastatic castration-naive prostate cancer: Results from LATITUDE. (2018) (1)
- Presenting Stage and Risk Group in Men Dying of Prostate Cancer. (2020) (1)
- Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial. (2015) (1)
- Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE. (2023) (1)
- Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA (2022) (1)
- Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study (2019) (1)
- Identification and functional characterization of a long non-coding RNA driving hormone-independent prostate cancer progression. (2015) (1)
- Longer follow-up data of circulating miR371a-3p expression across the spectrum of germ cell tumors (GCT). (2021) (1)
- The molecular and pathway characterization of patients with metastatic castration resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2014) (1)
- Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC). (2019) (1)
- Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial (2020) (1)
- A phase I dose escalation pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly and twice weekly erlotinib in advanced stage solid malignancies (2007) (1)
- Abstract A12: Identification of pathways associated with abiraterone resistance in metastatic castration resistant prostate cancer: Preliminary results from the SU2C/AACR West Coast Prostate Cancer Dream Team (2015) (1)
- 1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH (2022) (1)
- Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. (2023) (1)
- Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer. (2018) (0)
- What Antisense Oligonucleotides Have Promise in Prostate Cancer (2006) (0)
- 262 INVITED From New Targets to New Drugs in Prostate Cancer – Other Targets (2011) (0)
- Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies. (2022) (0)
- Chemotherapeutic Agents for Urologic Oncology: Basic Principles (2020) (0)
- Lymphovascular invasion in clinical stage I testicular nonseminoma: Potential marker of more aggressive relapses and implications for active surveillance. (2011) (0)
- Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians. (2020) (0)
- 2560 Baseline serum clusterin level in patients with poor prognostic features was associated with response to custirsen treatment: Results from the phase 3 SYNERGY trial of docetaxel +/- custirsen (2015) (0)
- Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial (2016) (0)
- Olaparib for the treatment of metastatic prostate cancer. (2021) (0)
- CUAJ – Review Kolinsky et al Germline and somatic genetic testing in prostate cancer treatment (2021) (0)
- Abstract A194: A QT/QTc and multi-dose pharmacokinetic (PK) study of abiraterone acetate (AA) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (2011) (0)
- Genomic analysis of circulating cell-free DNA (cfDNA) to investigate mechanisms of primary and acquired resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC). (2015) (0)
- Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients (2016) (0)
- Detection of clinically-actionable alterations as hallmarks of de novo small cell prostate cancer. (2018) (0)
- A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes (2023) (0)
- Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ) versus the opposite sequence for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized clinical trial. (2020) (0)
- Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. (2023) (0)
- A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC). (2013) (0)
- MP13-20 SECOND-GENERATION ANTISENSE OLIGONUCLEOTIDE - HSP27 A NEW INTRAVESICAL TREATMENT FOR BLADDER CANCER: PHASE 1CLINICAL TRIAL. (2016) (0)
- Real-world outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving dual immune checkpoint inhibitor (ICI-ICI) regimens or immune checkpoint inhibitor and tyrosine kinase inhibitor (ICI-TKI) combinations as first-line therapy: A British Columbia (BC) population-based analysis. (2023) (0)
- Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
- Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC) (2019) (0)
- MP92-13 NOVEL COMBINATION TREATMENT (OGX427/ SORAFENIB) ENHANCES SENSITIVITY IN RENAL CELL CARCINOMA (2016) (0)
- External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
- Abstract IA28: Targeting stress-induced molecular chaperones CLU and Hsp27 to inhibit EMT and metastases (2013) (0)
- Abstract 359: Molecular signatures associated with long-term response to apalutamide (APA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in TITAN (2021) (0)
- Abstract 3625: Clonal architecture and evolution of treatment-resistant prostate cancer via deep whole-genome ctDNA sequencing (2022) (0)
- 158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study (2022) (0)
- Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) (2019) (0)
- Management of Castration-Resistant Prostate Cancer: First-Line Therapy (2019) (0)
- 363 ABERRANT SONIC HEDGEHOG SIGNALING IN RENAL CELL CARCINOMA (2010) (0)
- Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET/CT-directed radiotherapy or surgery without systemic therapy (2023) (0)
- External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
- First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer. (2023) (0)
- Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer (2013) (0)
- Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy (2019) (0)
- Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer (2019) (0)
- Comprehensive immune profiling of patients (pts) with metastatic urothelial cancer (mUC) or renal cell cancer (mRCC) receiving immune checkpoint inhibitors (CPIs). (2020) (0)
- Correlation of AR-V7 expression in whole blood with efficacy of abiraterone acetate (ABI) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts). (2016) (0)
- DEFORMABILITY BASED SEPARATION OF CIRCULATING TUMOR CELLS FROM PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (2014) (0)
- Randomized, D ouble-Blind, C ontrolled T rial o f M itoxantrone/ Prednisone a nd C lodronate V ersus M itoxantrone/Pre dnisone and P lacebo i n P atients W ith H ormone-Refracto ry P rostate Cancer a nd P ain (2003) (0)
- Abstract CT190: Latin American patient subgroup analysis of the phase 3 TITAN study: Apalutamide plus ADT in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (2021) (0)
- Targeting Cell Survival Genes Using Antisense Oligonucleotides to Improve Chemo- and Hormonal-Therapies in Prostate Cancer (2002) (0)
- Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer (2008) (0)
- Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study. (2023) (0)
- Abiraterone in Metastatic Prostate Cancer. (2017) (0)
- 7056 POSTER QT/QTc Studies of Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) – Analysis of 3 Phase 1/2 Studies (2011) (0)
- 7130 POSTER Does Chemotherapy for Testicular Cancer Warrant Prophylactic G-CSF? (2011) (0)
- ARetrospective,Canadian Multi-Center Study Examining the Impactof Prior Response to Abiraterone Acetate on Eff|cacyofDocetaxelinMetastaticCastration-Resistant Prostate Cancer (2014) (0)
- O10 Enzalutamide, an androgen receptor signaling inhibitor, improves overall survival, time to first skeletal related event and pain (2012) (0)
- Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. (2023) (0)
- Targeting Hsp27 for the treatment of castrate-resistant prostate cancer (2011) (0)
- PD-147 A phase I study of a second generation antisenseoligonucleotide to clusterin (OGX-011) in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Preliminary results (2005) (0)
- 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). (2022) (0)
- Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. (2022) (0)
- The neoadjuvant management of muscle-invasive bladder cancer (MIBC) in Canada: A national survey of urologists. (2012) (0)
- Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase III study (2019) (0)
- 7014 A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive Castrate Resistant Prostate Cancer (CRPC) (2009) (0)
- Progress in the treatment of mCrPC (2014) (0)
- Abstract A24: Identifying the genomic and clinical features of AKT1/PIK3CA mutant metastatic prostate cancer using circulating tumor DNA (2020) (0)
- Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC). (2017) (0)
- Abstract PR08: The genomic landscape of metastatic urothelial carcinoma from circulating tumor DNA (2020) (0)
- Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results. (2023) (0)
- DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team. (2018) (0)
- Expression of circulating miR375 and miR371 to differentiate teratoma and viable germ cell tumor in patients with post-chemotherapy residual disease. (2020) (0)
- Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial. (2017) (0)
- Managing CRPC: improving symptoms, survival, or both? (2011) (0)
- Clinical implications of genomic alterations in metastatic prostate cancer (2021) (0)
- 209 A phase 1 clinical trial assessing an intravesical administered second-generation antisense oligonucleotide targeting heat shock protein 27 in bladder cancer (2016) (0)
- Reply to A. Edward Friedman’s Letter to the Editor re: Kim N. Chi, Anders Bjartell, David Dearnaley, et al. Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. Eur Urol 2009;56:594–605 (2010) (0)
- 608P Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC) (2021) (0)
- Systemic Therapy for Castrat ion-res is tant Prostate Cancer : Novel Agents and New Standards (2011) (0)
- A population-based analysis of the effectiveness of docetaxel for castration-sensitive prostate cancer (CSPC). (2018) (0)
- Molecular profiling of metastatic castration-resistant prostate cancer (mCRPC): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). (2014) (0)
- Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. (2023) (0)
- MP27-17 NIRAPARIB WITH ABIRATERONE ACETATE AND PREDNISONE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM THE PHASE 2 QUEST STUDY (2022) (0)
- Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer. (2022) (0)
- Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa) (2021) (0)
- PD14-09 CIRCULATING TUMOR DNA PRIOR TO THERAPY INITIATION IN DE NOVO METASTATIC PROSTATE CANCER (2018) (0)
- Circulating tumour DNA abundance and potential utility in de novo metastatic prostate cancer (2019) (0)
- Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC) (2019) (0)
- Evolution of management of testicular seminoma: Population-based outcomes with decreased utilization of active therapies. (2010) (0)
- 227: Effect of Timing and Sequencing of Castration and Chemotherapy on Time to Androgen-Independent Progression in Shionogi Tumor Model (2005) (0)
- Problems Identified With Phase II Stopping Rules That Employ Response and Early-Progression Rates (2008) (0)
- Predictive and prognostic biomarkers for next-generation hormonal agents in castration resistant prostate cancer (2015) (0)
- Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer (2021) (0)
- Analysis of AR-driven resistance mechanisms in a phase 1/2 study of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. (2016) (0)
- Exploratory analyses of incidence of skin rash and efficacy with apalutamide (APA) treatment of patients (pts) with advanced prostate cancer in SPARTAN and TITAN studies (2021) (0)
- Abstract PR09: Frequency and etiology of ctDNA-positive metastatic prostate cancer with BRCA2, ATM, or CDK12 mutations (2020) (0)
- Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study (2019) (0)
- Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)
- 178: Evaluating the Optimal Location of Radium 223 Treatment Facilities Based on Patient Travel Time (2016) (0)
- 845 Timing of the development of metastasis and initiation of treatment are important prognostic factors in prostate cancer (2016) (0)
- Sequence analysis SiNVICT : ultrasensitive detection of single nucleotide variants and indels in circulating tumour DNA (2016) (0)
- Dehydroepiandrosterone in metastatic castration-resistant prostate cancer: Preliminary results from the SU2C-PCF West Coast Dream Team (WCDT). (2016) (0)
- 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text. (2022) (0)
- Abstract CT302: Pharmacokinetics (PK) and safety of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (2015) (0)
- Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation (2022) (0)
- Reply by the Authors (2010) (0)
- Study of Combination Neoadjuvant Hormone Therapy and Weekly OGX-011 (Clusterin Antisense Oligonulceotide) Prior to Radical Prostatectomy in Patients with Localized Prostate Cancer. Phase 1 and 2 (2007) (0)
- Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery (2010) (0)
- Plasma exosome microRNAs in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab: Potential biomarkers of response to therapy. (2021) (0)
- Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review (2021) (0)
- Phase I/II Study of Combination Neoadjuvant Hormone Therapy and Weekly OGX-011 (Clusterin Antisense Oligonulceotide) Prior to Radical Prostatectomy in Patients with Localized Prostate Cancer (2008) (0)
- Abstract 3541: Biallelic alterations in BRCA2, ATM, or CDK12 in metastatic prostate cancer via circulating tumor DNA (2020) (0)
- A Phase 2 Study of GW786034 (Pazopanib) with or without Bicalutamide in Patients with Castration Resistant Prostate Cancer (2015) (0)
- Update on metastatic hormone-sensitive prostate cancer. (2022) (0)
- A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. (2012) (0)
- Autoantibody landscape of advanced prostate cancer (2020) (0)
- IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer (2022) (0)
- Machine-learning to predict utility of circulating tumor DNA (ctDNA) for somatic genotyping. (2023) (0)
- Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7. (2015) (0)
- The impact of time to metastasis on survival in treatment-naïve prostate cancer patients. (2015) (0)
- 585P Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC) (2021) (0)
- Encouraging Data from Phase I Studies of Astex ’ s Anti-Cancer Drugs AT 7519 , AT 9283 and AT 13387 to be Presented at EORTC-NCI-AACR Annual Meeting (0)
- Longitudinal evaluation of plasma miR371 to detect minimal residual disease and early relapse of germ cell tumors. (2023) (0)
- Treatment outcomes for patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) pts and DNA damage repair gene mutations. (2018) (0)
- Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma. (2017) (0)
- Serum neuroendocrine (NE) markers and clinical characteristics of treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) in men with metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team. (2018) (0)
- Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi). (2018) (0)
- A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer 1 (2002) (0)
- Abiraterone in Metastatic Prostate Cancer. (2017) (0)
- 1103 POSTER Overexpression of MiR-141 and MiR-126 Distinguishes Metastatic Castration Resistant Prostate Cancer (mCRPC) From Localized Prostate Cancer (PCa) and Controls in Human Plasma (2011) (0)
- [18F]DCFPyL PET/CT imaging in prostate cancer patients: a prospective study on safety, lesion detection rate, and impact on management (2019) (0)
- 2504 Genomic predictive and prognostic factors from plasma cell-free DNA (cfDNA) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) commencing enzalutamide (ENZ) (2015) (0)
- 771PANALYSIS OF OVERALL SURVIVAL (OS) FOR PATIENTS (PTS) WITH DIFFERENT PROGNOSTIC RISK FACTORS TREATED WITH CABAZITAXEL AND PREDNISONE (CBZ + P) AFTER DOCETAXEL (D) IN THE TROPIC TRIAL. (2014) (0)
- PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC). (2019) (0)
- Docetaxel for Metastatic Cancer and Its Role in Combination Therapies for Advanced Prostate Cancer (2005) (0)
- Abstract 776: Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN (2020) (0)
- Local and systemic modulation of the PD-L1 pathway is a novel mechanism of Enzalutamide resistance in castration-resistant prostate cancer (2014) (0)
- 774 ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI) (2016) (0)
- Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC). (2020) (0)
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer (2019) (0)
- Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC). (2019) (0)
- Preclinical evidence that chemotherapy for prostate cancer should be given at the same time as androgen withdrawal (2005) (0)
- Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. (2023) (0)
- MP24-08 RELATIONSHIPS OF SITES AND BURDEN OF METASTASES WITH LONG-TERM OUTCOMES AND MOLECULAR SUBTYPES IN TITAN (2021) (0)
- Abstract A221: A phase II study of SB939 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC). (2011) (0)
- EP-1359: Pain response in a Population-based study of Radium-223 for Metastatic Prostate Cancer (2017) (0)
- Canadian consensus forum of key controversial areas in the management of advanced prostate cancer (2021) (0)
- Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). (2021) (0)
- 651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study (2020) (0)
- Sonolisib: Pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, Oncolytic (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kim Nguyen Chi?
Kim Nguyen Chi is affiliated with the following schools:
